Immatics (NASDAQ:IMTX) Sees Unusually-High Trading Volume

Shares of Immatics (NASDAQ:IMTX - Get Free Report) saw an uptick in trading volume on Friday . 434,994 shares were traded during trading, a decline of 7% from the previous session's volume of 465,479 shares.The stock last traded at $10.71 and had previously closed at $10.64.

Immatics Stock Performance

The firm's fifty day simple moving average is $11.05 and its 200-day simple moving average is $10.52. The stock has a market cap of $916.87 million, a P/E ratio of -8.17 and a beta of 0.69.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.09. The company had revenue of $17.14 million during the quarter, compared to the consensus estimate of $11.78 million. Immatics had a negative net margin of 179.67% and a negative return on equity of 43.58%. Analysts predict that Immatics will post -1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immatics

Large investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC lifted its stake in Immatics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company's stock valued at $121,000 after acquiring an additional 2,916 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Immatics during the 4th quarter valued at $232,000. Jump Financial LLC bought a new position in Immatics during the 3rd quarter valued at $469,000. Trexquant Investment LP bought a new position in Immatics during the 3rd quarter valued at $498,000. Finally, Superstring Capital Management LP bought a new position in Immatics during the 4th quarter valued at $834,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.